Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-547
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Administration
- Intravenous
01
Overview
ABBV-547 is an investigational pharmaceutical agent being developed by AbbVie and currently in early clinical evaluation, with limited public information available on its structure, molecular modality, or specific biological target. It is being studied in a first-in-human trial in adults in the United States and Japan, where single-dose administration is used to characterize safety, tolerability, and pharmacokinetics. The indication and detailed mechanism of action have not yet been disclosed in public registries, and ABBV-547 remains an exploratory pipeline asset without established efficacy or regulatory approvals.
02
Targets
IL-23 (Interleukin-23)
Beyond the preview
Go deeper on ABBV-547.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-547.